Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. Review uri icon

Overview

abstract

  • Metastatic renal cell carcinoma (RCC) remains a disease highly resistant to systemic therapy. Results of recent reports in the literature on prognostic factors and clinical trials for patients with metastatic RCC were reviewed. Small numbers of patients exhibit complete or partial responses to interferon and/or interleukin-2, but most patients do not respond and there are few long-term survivors. Therefore, the identification of new agents with better antitumor activity against metastases remains the highest priority of clinical investigation in this refractory tumor. Prospective identification of patients more likely to benefit from cytokine therapy could be used as a stratification factor in Phase III trials, and in risk-directed therapy.

publication date

  • June 27, 2003

Research

keywords

  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Identity

Scopus Document Identifier

  • 0038354576

PubMed ID

  • 12850525

Additional Document Info

volume

  • 46 Suppl